No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 5.2x · 10Y median 20.9x · 4th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:07:05.569Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for SeaStar Medical Holding Corporation (ICU) stock was $3.16 as of Oct 6, 2026, 11:04 AM EDT, down 10.99% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -45.1% · 3-year avg -70.7%/yr
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions.
Biotechnology · Denver, CO
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.95
Revenue Est.
$500000.00
Last Quarter Results
EPS
$-0.91
vs Estimate
$-0.97
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ICU | $8.97M | $3.16 | -10.99% | -45.14% | N/A | N/A | N/A |
| 2ADVB | $9.08M | $6.57 | +3.63% | -31.85% | N/A | N/A | vs ICU |
| 3JSPR | $9.35M | $0.57 | -3.00% | -76.03% | -62.51% | N/A | vs ICU |
| 4HCTI | $8.48M | $0.57 | -6.66% | -99.61% | N/A | N/A | vs ICU |
| 5HSCS | $8.31M | $3.85 | -11.69% | +17.75% | N/A | N/A | vs ICU |
| 6MEDS | $8.31M | $3.17 | -5.50% | -90.01% | -45.88% | -25.43% | vs ICU |
forward FY estimate
N/A
$615000.00
vs Estimate
$486500.00
Consensus Rating
Based on 2 analysts
Average Price Target
$10.00
+216.5% upside
Low
$8.00
Current
$3.16
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.95 | $-0.95 | $-0.95 | 1 |
| Quarter ending Dec 2026 | $-0.89 | $-0.89 | $-0.89 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.68 | $-3.66 | $-3.64 | 1 |
| FY 2027 | $-2.10 | $-2.09 | $-2.08 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $500000.00 | $500000.00 | $500000.00 | 1 |
| Quarter ending Dec 2026 | $500000.00 | $500000.00 | $500000.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.99M | $2.00M | $2.01M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| FY 2027 |
| $2.99M |
| $3.00M |
| $3.01M |
| 1 |
